Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc (RBOT) combines advanced robotics with virtual reality to transform minimally invasive surgery. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements and market position.
Access real-time information about surgical robotics innovations, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and clinical trial updates directly impacting the future of abdominal surgery techniques.
Key focus areas include 3D visualization systems, single-port surgical interfaces, and integration with existing hospital workflows. Stay informed about developments in robotic-assisted procedures that enhance surgical precision while reducing patient recovery times.
Bookmark this page for verified updates about RBOT's progress in medical robotics. Regularly updated content ensures you maintain current awareness of technological breakthroughs and industry partnerships shaping modern surgical practices.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced its financial results for Q3 2022, reporting a significant increase in operating expenses to $22.2 million, up 159% from $8.6 million the previous year. R&D expenses rose to $12.1 million, while adjusted net loss was $21.7 million, or $0.18 per share, compared to a loss of $8.6 million, or $0.09 per share, in Q3 2021. The GAAP net loss was $24.7 million, down from $45.1 million year-over-year. The company ended the quarter with $126.8 million in cash and equivalents, maintaining a cash burn rate of $14.5 million.
Vicarious Surgical Inc. has signed a collaborative Memorandum of Understanding with Pittsburgh CREATES, enhancing its development of robotic surgical solutions. The partnership aims to leverage academic and clinical resources from the University of Pittsburgh and UPMC to improve surgical procedures' efficiency, outcomes, and cost-effectiveness.
This collaboration extends Vicarious Surgical's existing partnerships, providing access to a network of clinical and operational robotic experts.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) plans to release its third quarter 2022 financial results on November 7, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern Time. This company focuses on enhancing surgical procedures through innovative robotics aimed at improving efficiency and reducing healthcare costs. Founded in 2014, Vicarious Surgical is supported by notable investors including Bill Gates and Khosla Ventures. Investors can access the call by dialing +1 (646) 904 5544 (domestic) or +1 (929) 526 1599 (international).
Vicarious Surgical Inc. announced the resignation of board members Dror Berman and Samir Kaul effective October 18, 2022. The company appointed Beverly Huss to the board on the same date, where she will serve on the Audit Committee. Huss brings extensive experience in medical devices and has previously held CEO positions at companies like Pagonia Medical and Qool Therapeutics. The company aims to enhance surgical procedures through innovative robotic technology.
Vicarious Surgical Inc. (RBOT) has announced a Demonstration Day for its Beta 2 surgical robot prototype, scheduled for December 6, 2022, at 11:00 a.m. ET in Waltham, MA. The event is exclusive, with limited in-person attendance by invitation only, but will be live-streamed for broader access. The company aims to enhance surgical efficiency and patient outcomes through innovative robotics technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022, at 11:30 am ET. The virtual event aims to highlight emerging growth companies. Vicarious Surgical focuses on enhancing surgical efficiency and patient outcomes through advanced robotic technology. A live webcast will be available through a provided link, with an archived version accessible on their investor website following the event.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its Q2 2022 financial results, revealing a significant increase in operating expenses to $19.1 million, up from $6.6 million in Q2 2021. Adjusted net loss rose to $19.1 million, or $0.16 per share, compared to a loss of $6.6 million or $0.08 per share in the previous year. The company is advancing its Beta 2 system and partnering with UH Ventures and HCA Healthcare for surgical innovations. Cash burn rate for the quarter was $15.7 million. A conference call will be held today at 4:30 p.m. ET.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) has announced its participation in the Canaccord Genuity 42nd Annual Growth Conference set for Wednesday, August 10 at 9:30 a.m. ET. A live webcast of the presentation will be available on the company’s website, with an archive for later viewing. Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical is pioneering robotic technology aimed at enhancing surgical efficiency and patient outcomes while reducing healthcare costs.
Vicarious Surgical Inc. (NYSE: RBOT) will report its second quarter 2022 financial results on August 8, 2022, after market close. A conference call, open to investors, will begin at 4:30 p.m. Eastern Time. The company, founded in 2014, focuses on developing advanced robotics for minimally invasive surgery, aiming to enhance efficiency and reduce healthcare costs. Vicarious Surgical is backed by notable investors, including Bill Gates and Vinod Khosla, and is headquartered in Waltham, Massachusetts.
Vicarious Surgical has entered into Center of Excellence agreements with HCA Healthcare and University Hospitals Ventures. These partnerships aim to enhance the design and commercialization of the Company's robotic surgical system, incorporating real-world feedback from surgeons and healthcare administrators. This collaboration provides Vicarious Surgical with critical insights into surgical workflows, promoting the system's readiness for FDA approval. The partnerships are viewed as significant validation of its in-hospital potential, positioning Vicarious Surgical for future growth in the competitive healthcare market.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
